28,938 Shares in Solventum Corporation $SOLV Acquired by Arlington Partners LLC

Key Points

• Arlington Partners LLC has acquired a new stake in Solventum Corporation, purchasing 28,938 shares valued at approximately $2.2 million during the second quarter.
• Solventum's latest quarterly earnings beat analysts' expectations, reporting $1.69 EPS on revenue of $2.16 billion, with a return on equity of 29.93%.
• Analysts' ratings on Solventum have fluctuated, with one report indicating a consensus hold rating and several firms upgrading their target prices, with the highest now at $103.00.

Arlington Partners LLC acquired a new position in shares of Solventum Corporation (NYSE:SOLV - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 28,938 shares of the company's stock, valued at approximately $2,195,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rossby Financial LCC purchased a new stake in shares of Solventum in the 1st quarter valued at about $25,000. Strengthening Families & Communities LLC lifted its holdings in shares of Solventum by 376.8% in the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company's stock valued at $25,000 after purchasing an additional 260 shares during the last quarter. Hara Capital LLC purchased a new stake in shares of Solventum in the 1st quarter valued at about $38,000. Smartleaf Asset Management LLC lifted its holdings in shares of Solventum by 193.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company's stock valued at $40,000 after purchasing an additional 352 shares during the last quarter. Finally, Costello Asset Management INC purchased a new stake in shares of Solventum in the 1st quarter valued at about $42,000.

Analysts Set New Price Targets

SOLV has been the subject of several research reports. Jefferies Financial Group initiated coverage on Solventum in a report on Thursday, September 11th. They issued a "hold" rating and a $80.00 target price for the company. Wells Fargo & Company boosted their target price on Solventum from $79.00 to $82.00 and gave the company an "equal weight" rating in a report on Monday, September 15th. Wall Street Zen downgraded Solventum from a "strong-buy" rating to a "buy" rating in a report on Tuesday, September 9th. Zacks Research raised Solventum from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 15th. Finally, Argus raised Solventum from a "hold" rating to a "buy" rating and set a $90.00 price objective for the company in a research note on Tuesday, July 1st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $85.44.

Solventum Stock Performance

Shares of SOLV stock traded up $0.07 during trading hours on Monday, reaching $73.79. 1,484,158 shares of the company's stock were exchanged, compared to its average volume of 1,045,100. The company has a market cap of $12.79 billion, a P/E ratio of 34.16, a price-to-earnings-growth ratio of 3.00 and a beta of 0.53. The company's 50 day moving average is $72.97 and its two-hundred day moving average is $72.32. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $85.92. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86.

Solventum (NYSE:SOLV - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.45 by $0.24. The business had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The company's revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Equities research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.